On Friday, we wrote of Vytorin, that “we haven’t yet seen the 10b-5 securities fraud class actions.”
Well, that wasn’t a very long wait. Some things are just all too predictable.
The definitive source for intelligent commentary on the law that matters for drug and device product liability cases
On Friday, we wrote of Vytorin, that “we haven’t yet seen the 10b-5 securities fraud class actions.”
Well, that wasn’t a very long wait. Some things are just all too predictable.